Combination therapy with endocrine agents and broadly active small molecule inhibitors of BCL2 family members may delay, prevent, or reverse the acquisition of antiestrogen resistance in breast cancer patients and lead to significant improvements in survival. Here, BCL2 is linked to breast cancer.